679 Transduction of ferret airway, liver and pancreas following a single dose of adeno-associated virus 1

Autor: M. Yanda, A. Zeidan, W. Guggino, L. Cebotaru

Publikováno v: Journal of Cystic Fibrosis. 21:S371-S372

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4cce011f63e296add9a46afe3b174f2b
https://doi.org/10.1016/s1569-1993(22)01369-8

P025 The PDZ-containing domain protein, CAL links CFTR to the regulation of inflammation

Autor: L. Cebotaru, W. Guggino

Publikováno v: Journal of Cystic Fibrosis. 18:S64

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecd73c4adb12626f3a5e1a40c3e68def
https://doi.org/10.1016/s1569-1993(19)30320-0

Diagnostics

Autor: T. R. Einert, G. Schmidt, G. Binnig, O. Balacescu, L. Balacescu, M. Rus, R. Buiga, O. Tudoran, N. Todor, V. Nagy, A. Irimie, I. Neagoe, R. Yacobi, E. Ustaev, R. R. Berger, I. Barshack, K. Kaur, S. Henderson, A. Cutts, E. Domingo, J. Woods, C. Motley, B. Dougherty, M. Middleton, B. Hassan, Y. Wang, E. Beasley, M. Naley, A. Schuh, I. Tomlinson, J. Taylor, D. Planchard, B. Lueza, A. Rahal, L. Lacroix, M. Ngocamus, N. Auger, P. Saulnier, P. Dorfmuller, T. Le Chevalier, A. Celebic, J. P. Pignon, J. C. Soria, B. Besse, Y. H. Sun, R. Wang, C. G. Li, Y. J. Pan, H. Q. Chen, L. Chouchane, J. Shan, D. Kizhakayil, I. Aigha, S. Dsouza, B. Noureddine, S. Gabbouj, R. Mathew, E. Hassen, S. Shan, K. al-Rumaihi, I. al-Bozom, S. al-Said, D. Rabah, K. Farhat, I. A. Jakobsen Falk, K. H. Z. Green, K. Lotfi, A. Fyrberg, T. Pejovic, H. Li, P. Mhawech-Fauceglia, M. Hoatlin, M. G. Guo, M. Huang, Y. Ge, K. Hess, C. Wei, W. Zhang, T. A. Bogush, E. A. Dudko, M. V. Nureev, A. A. Kamensky, B. E. Polotsky, S. A. Tjulandin, M. I. Davydov, M. Caballero, J. Hasmats, H. Green, M. Quanz, C. Buhler, J. S. Sun, M. Dutreix, C. L. Cebotaru, A. N. Placintar, N. Ghilezan, Z. B. Balogh, L. Reiniger, H. Rajnai, J. Csomor, A. Szepesi, A. Balogh, L. Deak, E. Gagyi, C. Bodor, A. Matolcsy, V. K. Bozhenko, N. I. Rozhkova, E. A. Kudinova, O. P. Bliznyukov, E. N. Vaskevich, I. D. Trotsenko, N. V. Kharchenko, I. V. Kiandarian, C. Pulito, I. Terrenato, A. Sacconi, F. Biagioni, M. Mottolese, G. Blandino, P. Muti, E. Falvo, S. Strano, F. Mori, F. Ganci, R. Covello, C. Zoccali, R. Biagini, G. A. Palmer, W. Wegdam, D. Meijer, G. Kramer, J. Langridge, P. D. Moerland, S. M. de Jong, J. P. Vissers, G. G. Kenter, M. R. Buist, J. M. F. G. Aerts, M. Milione, F. de Braud, R. Buzzoni, S. Pusceddu, V. Mazzaferro, A. Damato, G. Pelosi, M. Garassino, M. Broggini, M. Marabese, S. Veronese, M. Ganzinelli, O. Martelli, N. Bossel, G. Fontemaggi, V. Manciocco, I. Sperduti, L. Strigari, G. Spriano, E. Domany, S. Donzelli, T. Bellissimo, G. Alessandrini, M. A. Carosi, E. Pescarmona, F. Facciolo, S. Telera, A. Pompili, V. de Vriendt, W. de Roock, A. F. di Narzo, S. Tian, B. Biesmans, B. Jacobs, J. de Schutter, E. Budzinska, X. Sagaert, M. Delorenzi, I. Simon, S. Tejpar, Y. Zhu, H. K. Wang, D. W. Ye, E. Denisov, M. Tsyganov, L. Tashireva, M. Zavyalova, V. Perelmuter, N. Cherdyntseva, Y. C. Kim, T. Jang, I. J. Oh, K. S. Kim, H. Ban, K. J. Na, S. J. Ahn, H. Kang, W. J. Kim, C. Park, N. K. Abousamra, M. S. El-Din, E. A. Azmy

Publikováno v: Annals of Oncology. 23:v12-v22

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a9221dcebee89d7f4256ae257063085
https://doi.org/10.1093/annonc/mds161

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Autor: Sinil Kim, Cristina L Cebotaru, Antonella Ingrosso, Paul Bycott, Igor Bondarenko

Publikováno v: BMC Cancer

Background Axitinib is an orally active and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemother

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae978b1224498594f150c7ca35209bd
https://doi.org/10.1186/s12885-015-1350-6

Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Autor: Martin Reck, Matthew Joseph Gribbin, Mircea Dediu, David R. Spigel, Cristina L. Cebotaru, D. Ross Camidge, Robin Humphreys, Jimmie H. Harvey, Joachim von Pawel, N. L. Fox

Publikováno v: Clinical lung cancer. 15(3)

Background This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non–small-cell lung cancer (NSCLC). Patients and Methods Patients with stage IIIB or stage IV advanced primary NSCLC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f43923140a95d16e2f6fffd8feef9da
https://pubmed.ncbi.nlm.nih.gov/24560012